Results 171 to 180 of about 20,339 (191)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study. [PDF]

Orphanet J Rare Dis
Chen T, Chen Q, Ye J, Wu Y, Liu T, Zhang Y.   +5 more
europepmc   +1 more source

Concomitant use of psychotropics and donepezil in Japanese patients with dementia: Pooled postmarketing surveillance data analysis

, 2016
Kasumi Daidoji, Yukinori Sakata, Kenta Sumitomo, Mika Ishii, Tetsumi Toyoda, Mika Kawaguchi   +5 more
openalex   +1 more source

An Evaluation of VYC-17.5L for the Treatment of Marionette Lines: A Prospective, Open-Label, Postmarketing Study. [PDF]

J Cosmet Dermatol
Cueto SRD, Urdiales Galvez F, Gritti A, Kefalas N, de la Guardia C, Kerson G.   +5 more
europepmc   +1 more source

Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process [PDF]

, 2011
Kassel, Mark A.
core   +1 more source

Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings. [PDF]

Res Pract Thromb Haemost
Kelly RJ, Nishimori H, Horneff R, Hillmen P, Al-Adhami M, Lallier S, Gerber GF.   +6 more
europepmc   +1 more source

Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding. [PDF]

Clin Cancer Res
Cortes JE, Abruzzese E, Cardonick EH, Hernández-Díaz S, Gutierrez J, Sardegna MS, Torres-Chavez E, Dinatale M, Lerro CC, Gehrke BJ, Shord SS, De Claro RA, Theoret MR, DeMaria PJ, Norsworthy KJ.   +14 more
europepmc   +1 more source

Accelerated drug approvals and patient trust: impact of voxelotor and crizanlizumab for sickle cell disease. [PDF]

Blood Adv
Karkoska K, Jacob SA, McGann PT.
europepmc   +1 more source

Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.

Vaccine
Ibarz-Pavon AB, Bielsky MC, Bose R, Cavaleri M, Crump JA, Hombach J, Kaslow DC, Khaman F, MacLennan CA, Mehring-LeDoare K, Pollard AJ, Quadri F, John J, Wilder-Smith A.   +13 more
europepmc   +1 more source

Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018. [PDF]

Am J Epidemiol
DiPrete BL, Dasgupta N, Oh GY, Moga DC, Slavova S, Slade E, Delcher C, Pence BW, Ranapurwala SI.   +8 more
europepmc   +1 more source

Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.

JAMA Netw Open
Mooghali M, Mohammad A, Wallach JD, Mitchell AP, Ross JS, Ramachandran R.   +5 more
europepmc   +1 more source